3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery

The article highlights three healthcare stocks—Medtronic, Sanofi, and Bristol Myers Squibb—that offer dividend yields of 3.3%, 5.0%, and 4.2% while investors wait for operational recovery. Medtronic posted Q3 fiscal 2026 revenue of $9.0B, up 8.7%, but margins and profits fell; Sanofi faces Dupixent patent risk despite 2025 sales of 4.2B euros; Bristol Myers is balancing a shrinking legacy portfolio against growth portfolio revenue that rose to $26.4B in 2025. Overall tone is cautious and income-focused rather than strongly bullish.

Analysis

The setup is less about yield and more about capital allocation under margin pressure. MDT looks like a classic “defensive income” name, but if tariff/input pressure persists, the dividend becomes a levered prop for the stock rather than a safety cushion; in that case, buybacks are less useful and the market will keep pricing in lower terminal margins. The more important read-through is for med-tech competitors: if MDT has to defend share via pricing or elevated R&D/SG&A, peers with cleaner margin structure and faster innovation cycles can steal incremental wallet share over the next 2-4 quarters.

SNY’s real risk is not the next quarter, but the transition period around a future Dupixent replacement. That creates a long-duration “show-me” state where even solid top-line guidance can fail to re-rate the stock unless the pipeline starts converting into visible launch revenue; in other words, the market will discount any guidance that leans on hope rather than product cadence. The new CEO adds optionality, but also extends governance uncertainty, which tends to suppress multiple expansion in European large-cap pharma until execution is demonstrated.

BMY is the cleanest relative value, but it is still a patent-cliff and leverage story dressed as a growth story. The key second-order effect is balance-sheet flexibility: any M&A use of cash/debt against a shrinking legacy cash engine can compress equity upside even if growth assets continue compounding, because the market will assign a lower multiple to earnings funded by financial engineering. The contrarian miss is that dividend screens can mask quality dispersion; the highest yield is not the best risk-adjusted setup if the payout is protecting a melting franchise rather than funding an inflection.

Key Decisions for Investors

• Prefer BMY over MDT on a 6-12 month horizon: long BMY / short MDT as a relative-value pair. Upside comes from BMY’s better momentum and growth-portfolio offset; risk is if MDT’s margin pressure proves temporary and rerates on clean execution.
• For income mandates, own SNY only as a defensive carry position, but cap size. Best entry is on any post-guidance pullback; target is 5-8% total return over 6 months mainly from yield, with limited multiple expansion until pipeline visibility improves.
• Avoid adding to MDT until gross-margin stabilization is visible for at least 1-2 quarters. If held already, consider selling covered calls 3-6 months out to monetize implied volatility while waiting for operating leverage to re-emerge.
• Use BMY as a dividend-plus-catalyst name, but hedge patent-cliff and M&A risk with a partial short in broader pharma or a collar structure; reward is mid-single-digit dividend plus potential re-rating if growth assets keep offsetting legacy decay.
• Watch for any incremental guidance cut or debt-funded deal announcement from BMY over the next 30-90 days; that would be the trigger to reduce exposure, because leverage plus declining legacy revenue is the most asymmetric downside in the group.